Patents Assigned to Helsinn Therapeutics (U.S.), Inc.
-
Patent number: 8673947Abstract: The present invention relates to method of enhancing the absorption of migraine medications and thereby treating migraines by co-administering to a subject in need thereof an effective amount of a ghrelin mimetic or pharmaceutically acceptable salt, hydrate or solvate thereof and at least one migraine medication selected from a serotonin 5-HT1B/1D receptor agonist, a tryptamine derivative, an ergoline derivative, a non-steroidal anti-inflammatory drug, or an analgesic, or any combination thereof.Type: GrantFiled: June 18, 2013Date of Patent: March 18, 2014Assignee: Helsinn Therapeutics (U.S.), Inc.Inventor: William J. Polvino
-
Publication number: 20130289068Abstract: The present invention relates to method of enhancing the absorption of migraine medications and thereby treating migraines by co-administering to a subject in need thereof an effective amount of a ghrelin mimetic or pharmaceutically acceptable salt, hydrate or solvate thereof and at least one migraine medication selected from a serotonin 5-HT1B/1D receptor agonist, a tryptamine derivative, an ergoline derivative, a non-steroidal anti-inflammatory drug, or an analgesic, or any combination thereof.Type: ApplicationFiled: June 18, 2013Publication date: October 31, 2013Applicant: Helsinn Therapeutics (U.S.), Inc.Inventor: William J. Polvino
-
Publication number: 20130281701Abstract: Crystalline forms of anamorelin which are useful as pharmaceutical agents are disclosed. Methods of production and isolation of these polymorphs and pharmaceutical compositions which include these polymorphs and pharmaceutical methods of treatment are also disclosed. The crystalline polymorphs of the present invention are useful as they act directly on the pituitary gland cells to release growth hormone.Type: ApplicationFiled: June 17, 2013Publication date: October 24, 2013Applicant: Helsinn Therapeutics (U.S.), Inc.Inventors: Keith Lorimer, Marcia Philipson, Bernhard Paul, Benjamin Littler
-
Patent number: 8486976Abstract: The present invention relates to method of enhancing the absorption of migraine medications and thereby treating migraines by co-administering to a subject in need thereof an effective amount of a ghrelin mimetic or pharmaceutically acceptable salt, hydrate or solvate thereof and at least one migraine medication selected from a serotonin 5-HT1B/1D receptor agonist, a tryptamine derivative, an ergoline derivative, a non-steroidal anti-inflammatory drug, or an analgesic, or any combination thereof.Type: GrantFiled: February 26, 2010Date of Patent: July 16, 2013Assignee: Helsinn Therapeutics (U.S.), Inc.Inventor: William J. Polvino
-
Patent number: 8466173Abstract: Crystalline polymorphs of (3R)-1-(2-methylalanyl-D-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide which are useful as pharmaceutical agents are disclosed. Methods of production and isolation of these polymorphs and pharmaceutical compositions which include these polymorphs and pharmaceutical methods of treatment are also disclosed. The crystalline polymorphs of the present invention are useful as they act directly on the pituitary gland cells to release growth hormone.Type: GrantFiled: July 6, 2010Date of Patent: June 18, 2013Assignee: Helsinn Therapeutics (U.S.), Inc.Inventors: Keith Lorimer, Seemon H. Pines, Paul Bernhard, Benjamin Littler
-
Patent number: 8394833Abstract: The present invention relates to methods of treating emesis by administering to the subject an effective amount of a growth hormone secretagogue compound or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 21, 2012Date of Patent: March 12, 2013Assignee: Helsinn Therapeutics (U.S.), Inc.Inventors: William R. Mann, William J. Polvino
-
Patent number: 8288427Abstract: A method of treating emesis with growth hormone secretagogues, particularly ipamorelin.Type: GrantFiled: April 10, 2008Date of Patent: October 16, 2012Assignee: Helsinn Therapeutics (U.S.), Inc.Inventors: William R. Mann, William J. Polvino
-
Publication number: 20120232113Abstract: The present invention relates to methods of treating or preventing emesis and improving a subject's ASAS score by administering to the subject an effective amount of a growth hormone secretagogue compound or a pharmaceutically acceptable salt, hydrate or solvate thereof.Type: ApplicationFiled: May 21, 2012Publication date: September 13, 2012Applicant: HELSINN THERAPEUTICS (U.S.), INC.Inventors: William R. Mann, William J. Polvino
-
Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues
Publication number: 20120077745Abstract: The present invention relates to a method of stimulating the motility of the gastrointestinal system in a subject in need thereof, wherein the subject suffers from maladies (i.e., disorders or diseases) of the gastrointestinal system. The method comprises administering to a subject in need thereof a therapeutically effective amount of a growth hormone secretagogue compound or a pharmaceutically acceptable salt, hydrate or solvate thereof. The growth hormone secretagogue can be co-administered with a laxative, a H2 receptor antagonist, a serotonin 5-HT4 agonist, an antacid, an opioid antagonist, a proton pump inhibitor, a motilin receptor agonist, dopamine antagonist, a cholinergic agonist, a cholinesterase inhibitor, somatostatin, octreotide, or any combination thereof.Type: ApplicationFiled: September 16, 2011Publication date: March 29, 2012Applicant: HELSINN THERAPEUTICS (U.S.), INC.Inventor: William J. Polvino -
Publication number: 20120010157Abstract: The present invention provides a method of stimulating the motility of the gastrointestinal system in a subject in need thereof, wherein the subject suffers from maladies (i.e., disorders, diseases, conditions, or drug- or surgery-induced dysfunction) of the gastrointestinal system, by administering to the subject a ghrelin mimetic, or pharmaceutically acceptable salt thereof. The invention also provides a method of treating a gastrointestinal malady by co-administering a ghrelin mimetic with a laxative, a H2 receptor antagonist, a serotonin receptor agonist, pure or mixed, an antacid, an opioid antagonist, a proton pump inhibitor, a motilin receptor agonist, dopamine antagonist, a cholinergic agonist, a cholinesterase inhibitor, somatostatin, octreotide, or any combination thereof.Type: ApplicationFiled: September 16, 2011Publication date: January 12, 2012Applicant: HELSINN THERAPEUTICS (U.S.), INC.Inventors: William J. Polvino, Richard Nelson, William R. Mann
-
Patent number: 8039456Abstract: The present invention provides a method of stimulating the motility of the gastrointestinal system in a subject in need thereof, wherein the subject suffers from maladies (i.e., disorders, diseases, conditions, or drug- or surgery-induced dysfunction) of the gastrointestinal system, by administering to the subject a ghrelin mimetic, or pharmaceutically acceptable salt thereof. The invention also provides a method of treating a gastrointestinal malady by co-administering a ghrelin mimetic with a laxative, a H2 receptor antagonist, a serotonin receptor agonist, pure or mixed, an antacid, an opioid antagonist, a proton pump inhibitor, a motilin receptor agonist, dopamine antagonist, a cholinergic agonist, a cholinesterase inhibitor, somatostatin, octreotide, or any combination thereof.Type: GrantFiled: November 26, 2008Date of Patent: October 18, 2011Assignee: Helsinn Therapeutics (U.S.), Inc.Inventors: William J. Polvino, Richard Nelson, William R. Mann
-
Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues
Patent number: 8039457Abstract: The present invention relates to a method of stimulating the motility of the gastrointestinal system in a subject in need thereof, wherein the subject suffers from maladies (i.e., disorders or diseases) of the gastrointestinal system. The method comprises administering to a subject in need thereof a therapeutically effective amount of a growth hormone secretagogue compound or a pharmaceutically acceptable salt, hydrate or solvate thereof. The growth hormone secretagogue can be co-administered with a laxative, a H2 receptor antagonist, a serotonin 5-HT4 agonist, an antacid, an opioid antagonist, a proton pump inhibitor, a motilin receptor agonist, dopamine antagonist, a cholinergic agonist, a cholinesterase inhibitor, somatostatin, octreotide, or any combination thereof.Type: GrantFiled: December 4, 2009Date of Patent: October 18, 2011Assignee: Helsinn Therapeutics (U.S.), Inc.Inventor: William J. Polvino -
Patent number: 7994329Abstract: Compounds that are ligands for the growth hormone secretagogue receptor type 1A (GHS-R 1A), as well as pharmaceutically acceptable salts of such compounds, are useful for the manufacture of medicaments for the regulation of food intake.Type: GrantFiled: June 19, 2006Date of Patent: August 9, 2011Assignee: Helsinn Therapeutics (U.S.), Inc.Inventor: Michael Ankerson
-
Publication number: 20110003996Abstract: Crystalline polymorphs of (3R)-1-(2-methylalanyl-D-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide which are useful as pharmaceutical agents are disclosed. Methods of production and isolation of these polymorphs and pharmaceutical compositions which include these polymorphs and pharmaceutical methods of treatment are also disclosed. The crystalline polymorphs of the present invention are useful as they act directly on the pituitary gland cells to release growth hormone.Type: ApplicationFiled: July 6, 2010Publication date: January 6, 2011Applicant: Helsinn Therapeutics (U.S.), Inc.Inventors: Keith Lorimer, Seemon H. Pines, Bernhard Paul, Benjamin Littler
-
Publication number: 20100317581Abstract: Injection and infusion solutions of ipamorelin, having the following composition: a) ipamorelin solubilized by approximately two molar equivalents of acetic acid (ipamorelin diacetate), in an amount of from 0.001 to 20%, based on the weight of the free base of ipamorelin; b) a molar excess of acid, preferably acetic acid, in an amount sufficient to give a pH of at least 3 and less than 7; c) optionally from 0.1 to 30% of one or more formulation aids; and d) water q.s. to 100%; all percentages based on the total weight of the solution.Type: ApplicationFiled: June 8, 2010Publication date: December 16, 2010Applicant: Helsinn Therapeutics (U.S.), Inc.Inventors: Silvina Garcia Rubio, Daniel E. Beidler, Helle Weibel, Riccardo Braglia
-
Patent number: 7825138Abstract: Crystalline polymorphs of (3R)-1-(2-methylalanyl-D-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide which are useful as pharmaceutical agents are disclosed. Methods of production and isolation of these polymorphs and pharmaceutical compositions which include these polymorphs and pharmaceutical methods of treatment are also disclosed. The crystalline polymorphs of the present invention are useful as they act directly on the pituitary gland cells to release growth hormone.Type: GrantFiled: June 22, 2005Date of Patent: November 2, 2010Assignee: Helsinn Therapeutics (U.S.), Inc.Inventors: Keith Lorimer, Seemon H. Pines, Bernhard Paul, Benjamin Littler
-
Publication number: 20100222388Abstract: The present invention relates to method of enhancing the absorption of migraine medications and thereby treating migraines by co-administering to a subject in need thereof an effective amount of a ghrelin mimetic or pharmaceutically acceptable salt, hydrate or solvate thereof and at least one migraine medication selected from a serotonin 5-HT1B/1D receptor agonist, a tryptamine derivative, an ergoline derivative, a non-steroidal anti-inflammatory drug, or an analgesic, or any combination thereof.Type: ApplicationFiled: February 26, 2010Publication date: September 2, 2010Applicant: Helsinn Therapeutics (U.S.), Inc.Inventor: William J. Polvino
-
Method of Stimulating the Motility of the Gastrointestinal System Using Growth Hormone Secretagogues
Publication number: 20100087381Abstract: The present invention relates to a method of stimulating the motility of the gastrointestinal system in a subject in need thereof, wherein the subject suffers from maladies (i.e., disorders or diseases) of the gastrointestinal system. The method comprises administering to a subject in need thereof a therapeutically effective amount of a growth hormone secretagogue compound or a pharmaceutically acceptable salt, hydrate or solvate thereof. The growth hormone secretagogue can be co-administered with a laxative, a H2 receptor antagonist, a serotonin 5-HT4 agonist, an antacid, an opioid antagonist, a proton pump inhibitor, a motilin receptor agonist, dopamine antagonist, a cholinergic agonist, a cholinesterase inhibitor, somatostatin, octreotide, or any combination thereof.Type: ApplicationFiled: December 4, 2009Publication date: April 8, 2010Applicant: Helsinn Therapeutics (U.S.), Inc.Inventor: William J. Polvino